The Science of HBV Cure Meeting 2024 Scientific Programme

July, 2024

26

Programme Time (SGT)
Welcome Remarks by the Conference Chairman
Opening Symposium: Overview of HBV Functional Cure
Moderators: Prof. Pietro Lampertico, Prof. Seng Gee Lim
HBV Cure: definitions and prospects
Prof. Pietro Lampertico, Italy
The Role of ICE-HBV in HBV functional cure
Prof. Massimo Levrero, France
Are HBV flares necessary for functional cure?
Prof. Kumar Visvanathan, Australia
Virological Insights into functional cure
Moderators: Prof. Thomas Tu, Dr. Jayantha Gunaratne
Is cccDNA silenced or lost in functional cure?
Prof. Massimo Levrero, France
Removing integrated HBV
Prof. Thomas Tu, Australia
New virological targets leading to functional cure
Prof. Pei Jer Chen, Taiwan
Free Paper: The role of HBx in functional cure
Dr. Aravind Sivakumar, Singapore
Free paper: BMP pathway is a target for functional cure
Dr. Jayantha Gunaratne
Free paper: HBV functional cure is related to baseline qHBsAg and interferon response
Prof. Seng Gee Lim, Singapore
Lunch
Immunological insights into functional cure 
Moderator: Dr. Valerie Chew
What we have learnt from interrogating the liver microenvironment : A review
Dr. Ram DasGupta, Singapore
Understanding the immune mechanisms to achieve functional cure
Prof. Eui-Cheol Shin, Korea
Free Paper Presentations
Free paper: The Role of STING Signaling Pathway in Chronic Hepatitis B: Implications for Immune Status
 Dr. Zhang Mingyuan
Animal Models  
Moderator: Prof. Eui-Cheol Shin, Prof. Massimo Levrero
A humanized animal model with matching immune system
Dr. Qingfeng Chen, Singapore
Animal model forum: How to use animal models in HBV drug development
Prof. Pei-Jer Chen, Dr. Qingfeng Chen, Dr. Guofeng Cheng, Dr. Zhi Hong
Capsid Assemby Modulators
Moderator: Prof. Harry Janssen
The role of Capsid Assembly Modulators in functional cure
Prof. Man Fung Yuen, Hong Kong
Invited Pharma Presentations
Moderator: Prof. Harry Janssen
Preclinical Profiling of ABI-6250, a Novel Orally Bioavailable Small-Molecule Therapeutic Candidate for the Treatment of Chronic Hepatitis (Virtual)
Dr. Marc Windisch, Assembly Biosciences
Aligos Assets for HBV functional cure
Dr. Min Wu, Aligos Therapeutics
Tea Break
Biomarkers
Moderator: Prof. Seng Gee Lim
Biomarkers for functional cure
Prof. Man-Fung Yuen, Hong Kong
Free paper: progress in biomarker discovery for HBV functional cure
Dr. Zijie Lim, Singapore
Invited Pharma Presentations
The performance and clinical utility of novel highly sensitive iTACT-HBsAg and iTACT-HBcrAg assays
Dr. Kazuyoshi Miyamoto, Fujirebio
Your partner in HBV management (Virtual)
Dr. Mark Anderson, Abbott Diagnostics
Closing remarks
End of day 1

July, 2024

27

Programme Time (SGT)
Special Lecture
Moderators: Prof.Thomas Tu, Prof. Massimo Levrero
Gene Editing for complete cure: state of the art
Dr. Kosh Agarwal, United Kingdom
RNA interference
Moderators: Prof. Thomas Tu, Prof. Massimo Levrero
Anti-sense vs siRNA: can we explain the efficacy differences?
Prof. Pei-Jer Chen, Taiwan
Invited Pharma Presentations
Moderators: Prof. Thomas Tu, Prof. Massimo Levrero
Roche strategy for functional cure
Dr. Farouk Chughlay, Roche
Bepirovirsen immune mechanism of action may potentiate infected hepatocyte killing: Indirect evidence from B-together peripheral longitudinal biomarker analysis
Dr. Shilpy Joshi, GSK
AHB-137, a novel ASO for HBV Cure
Dr. Guofeng Cheng, Ausperbio Therapeutics Inc
Update on Nucleic Acid Polymers (Virtual)
Dr. Andrew Vaillant, Replicor
Tea Break
Delta Cure
Moderator: Prof. Lim Seng Gee
Path to Delta Cure
Prof. Heiner Wedemeyer, Germany
The role of NAPs in Delta Therapy (Virtual)
Dr. Andrew Valliant, Replicor
Immunology
Chair and moderator:  Dr. Valerie Chew
Insights into HBV Cure from studies of novel immune modulators (Virtual)
Prof. Antonio Bertoletti, Singapore
Free paper: The differentiation of Treg and Th17 cells in patients with chronic hepatitis B in different stages
Dr. Le Thi Thuy Hang, Vietnam
Lunch
Invited pharma Presentations
Moderators: Prof. Kumar Visvanathan
Characterisation of Selgantolimod (TLR8 agonist) against CHB (Virtual)
Dr. Frida Abramov, Gilead Sciences
Clonal amplification of peripheral CD8+ T cells is associated with clinical response to checkpoint blockade in chronic hepatitis B (Virtual)
Dr. Jeff Wallin, Gilead Sciences
Insights into CHB functional cure from Ascletis studies (Virtual)
Dr. Jinzi J. Wu, Founder, Chairman and CEO, Ascletis
Achieving breakthroughs in HBV Cure
Dr. Zhi Hong, Brii Bio
siRNA+Neutralizing antibody combination for HBV Cure
Dr. Wang Dong, Hepa Thera
The potential role for a novel class, a Checkpoint Modifier, in the functional cure of CHB: the science and clinical data from VRON-0200 (Virtual)
Dr. Sue Currie, Dr. Andrew Luber, Virion Therapeutics
Tea Break
Treatment strategies
Moderators: Prof. Heiner Wedemeyer
Potential of immune based therapies for functional cure: success and limitations
Prof. Tatsuya Kanto, Japan
The return of interferon in functional cure strategies – a step backwards?
Prof. Harry Janssen, Holland
Combination Therapy Forum
Moderators: Prof. Seng Gee Lim, Prof. Heiner Wedemeyer
Immunotherapy and antiviral therapy forum
Prof. Eui Choel Shin, Prof. Massimo Levrero, Prof. Thomas Tu, Prof. Harry Janssen, Prof. Pei-Jer Chen, Prof. Kumar Visvanathan, Dr. Zhi Hong, Dr. Melanie Paff, Dr. Guofeng Cheng

Closing remarks from Chairman